视觉中国图 长江商报消息●长江商报记者 黄聪 药明康德（603259.SH、02359.HK）正持续减持药明合联套现。 近日，药明康德发布的公告显示，公司通过大宗交易继续出售所持有的药明合联3030万股股票，约占药 明合联当前总股本的2.47%，成交金额约23.46亿港元。 长江商报记者统计显示，近一年来，药明康德累计减持药明合联股份套现69.5亿港元，按照当前汇率计算 合计63.72亿元人民币。 值得关注的是，2023年和2024年以及2025年上半年，药明康德研发费用连续下滑，两年半合计达31.94亿 元，占同期1003.81亿元营业收入比例仅为3.18%。 而且，近两年半来，药明康德员工人数减少了6529人，降幅达14.72%。 与此形成鲜明对比的是，2022年至2024年，药明康德董事长、执行董事、总裁（首席执行官）李革薪酬 分别为4196.9万元、4196.86万元和4180万元，三年拿走1.26亿元。 近一年四次减持药明合联 近日，药明康德发布的公告显示，公司通过大宗交易继续出售所持有的药明合联3030万股股票，约占药 明合联当前总股本的2.47%，成交金额约23.46亿港元（不包含手续费等交易费 ...

Core Viewpoint - WuXi AppTec is continuously reducing its stake in WuXi AppTec Holdings, having sold 30.3 million shares recently for approximately HKD 23.46 billion, which represents 2.47% of the total share capital of WuXi AppTec Holdings [2][4] Share Reduction and Financial Impact - Over the past year, WuXi AppTec has cumulatively reduced its holdings in WuXi AppTec Holdings, realizing approximately HKD 69.5 billion, equivalent to RMB 63.72 billion [2][7] - The recent sale is part of a strategy to accelerate global capacity and capability building, aiming to attract and retain talent while enhancing its integrated CRDMO business model [4][17] - The net investment gain from the recent sale is expected to impact the company's net profit for 2025 by approximately RMB 16.79 billion, accounting for over 10% of the latest audited net profit attributable to shareholders [4][5] R&D Expenditure Trends - WuXi AppTec's R&D expenses have been declining for two and a half years, totaling RMB 31.94 billion, which is only 3.18% of the total revenue of RMB 1003.81 billion during the same period [10][12] - R&D expenses for 2023 and 2024 were RMB 14.41 billion and RMB 12.39 billion, respectively, showing a decline of over 10% each year [10][12] - The company reported a significant drop in R&D expenses in the first half of 2025, amounting to RMB 5.14 billion, which is a 19.15% decrease year-on-year [12] Employee Reduction - WuXi AppTec has reduced its workforce by 6,529 employees over two and a half years, representing a 14.72% decrease [13][14] - Employee numbers decreased from 44,361 at the end of 2022 to 37,832 by mid-2025 [13][14] Executive Compensation - Despite workforce reductions, executive compensation remains high, with the chairman and CEO receiving a total of RMB 126 million over three years [15][16] Business Performance and Global Strategy - WuXi AppTec's revenue for the first half of 2025 reached RMB 207.99 billion, a year-on-year increase of 20.64%, with net profit growing by 101.92% [11] - The company is focusing on global expansion, with a backlog of orders amounting to RMB 566.9 billion, a 37.2% increase year-on-year [17]